Xilio Therapeutics goes public as biopharma IPOs rumble forward in Q4
It’s been a busy fall on Wall Street — and this week, we’ve got another biotech going public after Ventyx yesterday.
Massachusetts solid-tumor biotech Xilio Therapeutics made its public debut today, joining 149 other biotechs that have gone public so far this year.
Back on October 1st, Xilio filed its S-1 with the SEC to make its IPO debut for $100 million — the next step in financing after completing a $95 million Series C back in February.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.